Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Aline Jary
Long-Term Follow-Up of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Related publications
Intravenous Immunoglobulin Therapy Use in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated With Tisagenlecleucel in the Juliet Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Pcn72 - Budget Impact Analysis of Tisagenlecleucel for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in England
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Prolonged Improvement in Patient Reported Quality of Life (QoL) Following Tisagenlecleucel Infusion in Adult Patients (Pts) With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): 19-Month Follow-Up (FU) of the Juliet Study
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Annals of Hematology
Medicine
Hematology
Pcn177 - Cost-Effectiveness of Tisagenlecleucel for Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma : A Canadian Societal Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Cytokine Release Syndrome and Neurotoxicity by Baseline Tumor Burden in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With Tisagenlecleucel
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma
American Journal of Hematology
Hematology
